Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Sky One Close to Approval on Two Diagnostic Tests

publication date: Nov 26, 2009
China Sky One Medical expects to have final SFDA approval for two more diagnostic kits by the end of 2009. One is a diagnostic test for Human Prostate Specific Antigen, an indicator of prostate related diseases, and the other is a determination kit for Luteinizing Hormone, a diagnosis test for female sterility. China Sky One plans to begin production of the two tests in 2010. They will join the company’s relatively new diagnostic testing division, which currently consists of three kits and contributed 6% of the company’s Q3 revenues. More details...
Stock Symbol: (NSDQ: CSKI)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital